Around 20-25 % of pancreatic cancer patients deemed eligible for curative-intent surgery are found to be non-resectable during the initial explorative stages of surgery. These patients are therefore exposed to the risk and discomfort of surgery, i.e. bleeding, perforated bowel, impaired wound healing, pain, hospital admission, without any obvious benefits. Furthermore, survival seems to be poorer among patients undergoing non-therapeutic surgery compared with patients treated with up-front chemotherapy for metastatic disease. We therefore aim to explore if patient-characteristics, available at the time of MDT, are associated with non-resectable disease due to intraabdominal metastises or locally advanced disease.